Humana enters September with short sellers scaling back positions and the Street reshaping its view after a damaging stretch that now looks increasingly in the rearview mirror.
The most striking development this week is how quickly the bear camp has thinned. Short interest has dropped 14% over the past week and is down more than 21% over the past month, landing at 2.7% of the free float — a level so low it barely registers as a structural short thesis. That retreat coincided with the stock adding 8.5% over the past month to close at $394.88 on September 1, up 3% on the day alone. Shorts aren't fighting this rally anymore.
The lending market confirms the retreat isn't under stress. Borrow availability is essentially uncapped — shares available to lend dwarf those currently borrowed, with the availability ratio at the ceiling of the data range. Cost to borrow ticks along below 0.4%, which is negligible friction for anyone wishing to establish a new short position. The options market is equally calm. The put/call ratio at 0.84 is almost exactly in line with its 20-day average, sitting less than 0.1 standard deviations below the mean. Neither the borrow market nor the options desk is flashing any particular directional conviction. Positioning looks comfortable rather than charged.
The Street's recent moves tell the more interesting story. After a bruising period for managed care broadly, analysts have largely pivoted from skepticism toward cautious acceptance. JP Morgan lifted its target from $316 to $393 earlier in August while staying at Neutral — a substantial target move that still stops short of endorsing the rally. Morgan Stanley went further, upgrading from Underweight to Equal-Weight and raising its target from $249 to $370. Several other firms — Barclays, UBS, TD Cowen — raised targets in late July on the back of the Q2 print, though most held at Hold or Equal-Weight ratings. Evercore ISI was the standout bull, upgrading to Outperform with a $480 target. Raymond James took the other side, downgrading to Market Perform. The consensus mean target of $418.61 sits about 6% above the current price, a modest premium that reflects the Street's broadly constructive-but-not-euphoric posture. Factor scores reinforce the improving backdrop: EPS momentum ranks in the 92nd percentile over 90 days and the 82nd over 30 days, with forward earnings estimates showing a near-185% year-on-year increase as the Medicare Advantage margin recovery takes hold.
The bull and bear cases remain starkly drawn. On the positive side, Group Medicare Advantage margins expanded 500 basis points — the result of successful contract renegotiations — and the CenterWell pharmacy business grew revenue 16%. Bears counter with a concrete threat: a roughly $3.5 billion headwind from declining MA Star ratings that analysts estimate could drag 2026 EPS by approximately $22. The Star rating issue is not new news, but it is not resolved either. The stock has rallied hard on the margin improvement story; how durable that improvement proves against the Star rating headwind is the question the market is now pricing.
Among close peers, CVS has been the week's standout, up more than 5% over the past five sessions. CI and ELV each gained roughly 1-2.7% on the day Tuesday but trailed HUM's 3% daily move. UNH was broadly flat on the week. The managed care group is broadly recovering from its earlier-year lows, but HUM's stronger daily print suggests the market is giving it some catch-up credit.
The next scheduled earnings event is November 6. Between now and then, every update on Medicare Advantage Star ratings and any CMS signals on 2027 reimbursement rates carry more weight than usual — those are the datapoints that will determine whether the bear case or the bull case is winning.
See the live data behind this article on ORTEX.
Open HUM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
